Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443324 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT02443324 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 175 participants.
The verdict
NCT02443324, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).
Interventions
- DRUG Pembrolizumab
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2015-07-29 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443324
The ClinicalTrials.gov registry entry for NCT02443324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02443324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02443324 about?
NCT02443324 is a clinical study titled "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer". The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cel...
What is the current status of trial NCT02443324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2015-07-29. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT02443324?
The interventions under investigation include: Pembrolizumab (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02443324?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.